New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 16, 2012
07:49 EDTSNY, REGNSanofi, Regeneron report Zaltrap receives CHMP positive opinion
Sanofi (SNY) and Regeneron Pharmaceuticals (REGN) announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency adopted a positive opinion and recommended the granting of marketing authorization for Zaltrap Injection for Intravenous Infusion in combination with irinotecan/5-fluorouracil/folinic acid chemotherapy in adults with metastatic colorectal cancer that is resistant to or has progressed after an oxaliplatin-containing regimen. The European Commission now needs to ratify the positive opinion from CHMP to grant marketing authorization of Zaltrap in all 27 European Union member countries. A decision is expected from the European Commission in the first quarter of 2013. Zaltrap received approval from the U.S. Food and Drug Administration in August 2012 after Priority Review and marketing authorization applications for Zaltrap are under review with other regulatory agencies worldwide. In the U.S. Zaltrap is approved with the U.S. proper name ziv-aflibercept for use in combination with 5-fluorouracil, leucovorin, irinotecan, in patients with metastatic colorectal cancer that is resistant to or has progressed following an oxaliplatin-containing regimen.
News For SNY;REGN From The Last 14 Days
Check below for free stories on SNY;REGN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 29, 2014
12:23 EDTSNY, REGNNovartis drug data to be presented this weekend
Subscribe for More Information
10:06 EDTSNYSanofi unit treatment of Fabry's disease granted orphan status
Subscribe for More Information
08:18 EDTSNYPerrigo among companies showing interest in Omega Pharma, Bloomberg says
Subscribe for More Information
August 25, 2014
12:19 EDTSNYOn The Fly: Midday Wrap
Subscribe for More Information
11:48 EDTREGN, SNYSanofi and Regeneron co-host a conference call
Subscribe for More Information
10:40 EDTSNYBiotechs rise after InterMune acquired by Roche
Subscribe for More Information
August 22, 2014
12:39 EDTSNYThese five companies will benefit from increased ALS awareness, MarketWatch says
A recent surge in funding for Lou Gehrig's disease, or ALS, caused by the Ice Bucket challenge that is widespread on social media outlets, will benefit five pharmaceutical companies that are involved in the development of a cure for ALS, according to MarketWatch. The companies that are or have been involved in developing a treatment for ALS include Biogen Idec (BIIB), Avanir Pharmaceuticals (AVNR), Isis Pharmaceuticals (ISIS), Sanofi (SNY), and Bristol-Myers Squibb (BMY), MarketWatch added. Reference Link
August 21, 2014
05:42 EDTSNYIllumina announces strategic partnership with AstraZeneca, Sanofi, Janssen
Illumina (ILMN) announced it has formed collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation sequencing, or NGS,-based oncology test system. The system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multi-gene panel for therapeutic selection, resulting in a more comprehensive tool for precision medicine. Initial strategic partners include AstraZeneca (AZN), Janssen Biotech, a Johnson & Johnson (JNJ) company, and Sanofi (SNY). Illumina is working with the strategic partners to develop assays that detect and measure multiple variants simultaneously to support partners’ clinical trials, with the objectives of securing regulatory agency approvals and test commercialization. In parallel, Illumina is working with key thought leaders to set standards for NGS-based assays in routine clinical oncology practice, as well as to define regulatory frameworks to enable this new testing paradigm. Together, Illumina and its strategic partners aim to transition from single-analyte companion diagnostics to panel-based assays that select for “companion therapeutics.”
August 19, 2014
16:46 EDTSNYFDA approves Genzyme Cerdelga capsules
Subscribe for More Information
August 18, 2014
07:57 EDTREGNCambridge Healthtech Institute to hold a summit
6th Annual Bioprocessing Summit to be held in Boston on August 18-22.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use